Tepadina®
(thiotepa). An antineoplastic agent; an alkylating compound of the nitrogen mustard group.1
Indications
Tepadina is indicated for use in combination with other chemotherapeutic medicinal products:1
- as conditioning treatment in adults and children with hematologic diseases prior to allogeneic or autologous hematopoietic stem cell transplantation, with or without total body irradiation;
- for the treatment of solid tumors in adults and children as part of high-dose multimodal chemotherapy regimens supported by hematopoietic stem cell transplantation.
Dosage form
Lyophilisate for concentrate for solution for infusion, each vial contains thiotepa 15 mg or 100 mg.1
Age restrictions
Adults and children.1
Dosage regimen
The medicinal product is administered as an intravenous infusion. The dose depends on patient age, type of transplantation, and disease.1
Manufacturing and Registration
Name and legal address of the marketing authorization holder: ADIENNE SA, Via Zurigo, 46, 6900 Lugano, Switzerland.1
Manufacturing of the finished dosage form and primary packaging: BSP Pharmaceuticals S.p.A., 04013 Latina (Latina Scalo), Via Appia 65, km 561, Italy. Secondary packaging: SIT S.R.L., Via Primo Villa 17, 20875 Burago di Molgora (Monza e Brianza), Italy. Release quality control: ADIENNE SA, Via Zurigo, 46, 6900 Lugano, Switzerland.1
Authorized organization for receiving consumer complaints: Nanolek LLC, Russia, 123112, Moscow, Presnensky Municipal District, Testovskaya St., 10, premises 1/16. Tel.: +7 495 648-26-87 Email: info@nanolek.ru.1